Skip to main content
. 2022 Feb 21;79(4):349–358. doi: 10.1001/jamaneurol.2021.5578

Figure 3. Evidence of Atherosclerosis.

Figure 3.

Relative risk (RR) with 95% CI of recurrent stroke with more intensive vs less intensive low-density lipoprotein cholesterol–lowering statin-based therapies among patients with stroke having or not having evidence of atherosclerosis. Different sizes of markers indicate the different weights used for pooled analysis. CARE indicates the Cholesterol and Recurrent Events Study; FOURIER, Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk; HPS, Heart Protection Study; IMPROVE-IT, Improved Reduction of Outcomes: Vytorin Efficacy International Trial; J-STARS, Japan Statin Treatment Against Recurrent Stroke; LIPID, Long-term Intervention with Pravastatin in Ischaemic Disease; ODYSSEY OUTCOMES, Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; PODCAST, Prevention of Decline in Cognition after Stroke Trial; SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol Levels; and TST, Treat Stroke to Target.